EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Exploring Pembrolizumab‐Induced IM3OS in a Patient With Bladder Cancer

Ching-Cheng Chan, Ming-Jen Lee, Jian Su, Jen-Jen Su iD

Pharmacology Research & Perspectives · 2026-02 · 14 (1)

DOI: 10.1002/prp2.70212 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 26.01.2026. Verfasst von Ching-Cheng Chan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Urinary Bladder Neoplasms, Myasthenia Gravis, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pembrolizumab, an immune checkpoint inhibitor (ICI), has transformed cancer treatment across various malignancies, including metastatic urothelial cancer. As the use of pembrolizumab becomes increasingly widespread, understanding its potential adverse effects is essential. Here, we present the case of a 79‐year‐old male with urothelial cancer of the bladder, who experienced local recurrence after surgery and conventional therapies. He subsequently began pembrolizumab treatment. Following the first infusion, the patient developed a series of complications over a span of 26 days, including acute hepatitis, chest pain, and progressive bilateral ptosis. A third‐degree atrioventricular block was also detected, necessitating pacemaker implantation. Further neurophysiological evaluations confirmed a diagnosis of myasthenia gravis and myositis. The patient was treated with intravenous methylprednisolone, immunoglobulin therapy, and pyridostigmine bromide. Despite these interventions, his condition deteriorated, requiring intubation and mechanical ventilation 28 days post‐treatment. This case highlights that pembrolizumab can trigger rare but severe neurological and cardiovascular adverse events. Prompt and thorough investigations to identify syndromes such as myocarditis‐myositis‐myasthenia gravis overlap syndrome (IM3OS) are vital for timely diagnosis and intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedUrinary Bladder NeoplasmsMyasthenia GravisAntineoplastic Agents, ImmunologicalMyositisHumansMaleAged

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
  • Department of Neurology, National Taiwan University Hospital, Taipei City, Taiwan.
  • Department of Internal Medicine, MacKay Memorial Hospital, Taipei City, Taiwan.

ORCID-Profile: Jen-Jen Su

Zitieren

APA

Chan, C. C., Lee, M. J., Su, J., & Su, J. J. (2026). Exploring Pembrolizumab‐Induced IM3OS in a Patient With Bladder Cancer. Pharmacology Research & Perspectives, 14(1). https://doi.org/10.1002/prp2.70212

Vancouver

Chan CC, Lee MJ, Su J, Su JJ. Exploring Pembrolizumab‐Induced IM3OS in a Patient With Bladder Cancer. Pharmacology Research & Perspectives. 2026;14(1). doi:10.1002/prp2.70212

BibTeX
@article{Chan2026,
  author = {Chan, Ching-Cheng and Lee, Ming-Jen and Su, Jian and Su, Jen-Jen},
  title = {Exploring Pembrolizumab‐Induced IM3OS in a Patient With Bladder Cancer},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {1},
  doi = {10.1002/prp2.70212}
}
Kostenlos starten →